Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans
Vicebio Ltd (“Vicebio”), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory viruses, today announces its progress in the ongoing VXB-241 bivalent RSV-hMPV Phase 1 (P1) study as well as...

